Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis
24 Dec 2023
bởiStephen Padilla
Fedratinib is superior to the best available therapy (BAT) in terms of spleen volume reduction (SVR) and symptom response rates in patients with myelofibrosis (MF) treated with the Janus kinase inhibitor (JAKi) ruxolitinib, as shown in a study presented at ASH 2023.
24 Dec 2023

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma
22 Dec 2023
bởiStephen Padilla
First-line combination immuno-oncology therapy (IO) with ipilimumab and nivolumab provides beneficial effects and has an acceptable safety profile in patients with metastatic renal cell carcinoma, as shown in a Japan study presented at ESMO Asia 2023.
22 Dec 2023






